为放射治疗重新使用放射敏感药物:概述
Jie Man Low1, Gonzalo Rodriguez-Berriguete2, Geoff S Higgins2
1Department of Oncology, Oxford University Hospitals NHS Trust, Oxford, UK.
BMJ oncology
|January 31, 2025
概括
重新利用非癌症药物来增强瘤辐射敏感性,用于癌症治疗是有前途的. 然而,试验设计不佳和缺乏生物标志物的挑战阻碍了成功,需要为未来的药物重新定位努力进行战略改进.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 辐射疗法 辐射疗法
背景情况:
- 药物再利用提供了更快,更便宜的癌症治疗选择.
- 已建立的非癌症药物在与放射治疗 (RT) 结合时可能会增强瘤的放射敏感性.
研究的目的:
- 评估与放射治疗结合使用的重定向药物的景观.
- 确定有助于成功和不成功的药物再利用辐射敏感化的因素.
主要方法:
- 基于文献的方法被用于识别与RT或化疗放射治疗一起进入临床试验的放射敏感药物.
- 对临床试验数据的分析,用于成功和不成功的重定向努力.
主要成果:
- 确定了42种具有不同非癌症指示和作用机制的放射敏感药物.
- 尼古丁胺和尼莫拉是两种有限临床使用的化合物,具有RT.
- 不成功的转变用途的常见原因包括试验报告不佳,缺乏生物标志物,药物属性不理想和资金不足.
结论:
- 成功地重新定位RT的药物需要强大的试验设计,生物标志物识别,并考虑临床前和临床数据.
- 未来的努力应集中在缓解已识别的挑战,以提高放射治疗中重新定位药物的成功率.
关键词:
辐射疗法 辐射疗法
相关概念视频
01:20Desensitization and Tachyphylaxis
3.4K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.4K
01:17Drugs Used in Lower Respiratory Disorders: Overview
1.6K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.6K
01:13Radiological Investigation III: Pulmonary Angiogram and PET Scan
722
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
722
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
853
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Fundamental Principles of PET
853
01:19Modified-Release Drug Delivery Systems: Overview
236
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
236
01:30Drug Toxicity: Allergic Reactions
209
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
209